Trial · NCT02361424
Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)
NCT02361424, Phase 2, Completed, Pharnext S.C.A.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD). Trials, record NCT02361424. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02361424
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)
- NCT number
- NCT02361424
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 47 participants, actual
- Lead sponsor
- Pharnext S.C.A.
- Conditions
- Alzheimer Disease
- Interventions
- PXT00864, placebo
- First posted
- 2015-02-11
- Last updated
- 2016-02-15
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in the total score of the 11-item Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog) | Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4) | Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater cognitive impairment. |
| Primary | Number of Treatment Emergent Adverse Events (TEAEs) | throughout the 12-week study period. | |
| Secondary | Change From Baseline in the score of the Digit Symbol Substitution Test (DSST) | Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4) | Scores on the DSST range from 0-93 with lower scores indicating greater impairment. |
| Secondary | Change From Baseline in the speed to perform the Zazzo's Cancellation Test | Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4) | |
| Secondary | Change From Baseline in the score of the Zazzo's Cancellation Test | Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4) | |
| Secondary | Change From Baseline in the score of the 15-second Isaacs Set Test | Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4) | |
| Secondary | Change From Baseline in the time score of the Trail Making Test - part A | Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4) | |
| Secondary | Change From Baseline in the time score of the Trail Making Test - part B | Visit V0 (train), V1 (baseline), and every 4 weeks (visits V2, V3 and V4) | |
| Secondary | Change From Baseline in the score of the Free and Cued Selective Reminding Test (FCSRT) | 1 (baseline) and V4 (end of study, after 12 weeks of treatment) | FCSRT is a memory test administered according to the procedure described by Gröber and Buschke modified with 16 verbal items. |
| Secondary | Change From Baseline in the score of the 4-item Instrumental Activities of Daily Living scale (IADL-PAQUID) | V0 (train), V1 (baseline), and every 4 weeks (V2, V3 and V4) | The 4-item Instrumental Activities of Daily Living scale (IADL) concerns four routine daily functions (using transportation, managing finances, using the phone and managing medicines use). Scores on the IADL range from 4-15 with higher scores indicating greater impairment. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Cancellation Test | Secondary outcome | ConductCognition |
| Oddball Target Detection | Other outcome | ConductCognition |
| Selective Reminding Task | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02361424
GET https://conductscience.org/api/trials/v1/NCT02361424/registered